10 Dec
2024
14:50 E.S.T.

Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)

Read more

05 Nov
2024
16:30 E.S.T.

Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting

Read more

04 Nov
2024
16:30 E.S.T.

Cellectis Provides Business Updates and Financial Results for Third Quarter 2024

Read more

30 Oct
2024
16:30 E.S.T.

Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024

Read more

22 Oct
2024
02:00 E.S.T.

Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress

Read more

03 Sep
2024
11:05 E.S.T.

Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety

Read more

26 Aug
2024
10:35 E.S.T.

Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors

Read more

07 Aug
2024
02:00 E.S.T.

Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer

Read more

06 Aug
2024
16:30 E.S.T.

Cellectis Provides Financial Results for the Second Quarter 2024

Read more

01 Aug
2024
16:30 E.S.T.

FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment

Read more